Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Cash from Operations (2019 - 2026)

Immunovant filings provide 7 years of Cash from Operations readings, the most recent being 92325000.0 for Q4 2025.

  • Quarterly Cash from Operations rose 8.03% to 92325000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 422888000.0 through Dec 2025, down 30.15% year-over-year, with the annual reading at 375874000.0 for FY2025, 75.46% down from the prior year.
  • Cash from Operations hit 92325000.0 in Q4 2025 for Immunovant, up from 102515000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 20047000.0 in Q3 2021 and bottomed at 117411000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 60957650.0, with a median of 57746000.0 recorded in 2023.
  • The largest annual shift saw Cash from Operations tumbled 210.26% in 2022 before it rose 28.03% in 2023.
  • Immunovant's Cash from Operations stood at 31895000.0 in 2021, then crashed by 45.46% to 46395000.0 in 2022, then decreased by 1.52% to 47098000.0 in 2023, then plummeted by 113.15% to 100391000.0 in 2024, then grew by 8.03% to 92325000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Cash from Operations are 92325000.0 (Q4 2025), 102515000.0 (Q3 2025), and 117411000.0 (Q2 2025).